基于CRISPR/Cas9技术的β-地中海贫血和血友病基因治疗研究进展
收稿日期: 2020-04-21
修回日期: 2020-08-25
网络出版日期: 2020-09-15
基金资助
国家重点研发计划编号(2016YFC1000503);上海市重中之重重点学科项目编号(2017ZZ02019);上海市临床重点专科项目编号(shslczdzk05705)
Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology
Received date: 2020-04-21
Revised date: 2020-08-25
Online published: 2020-09-15
Supported by
Supported by the National Key Research and Development Program of China No(2016YFC1000503);Shanghai Key Disciplines Program No(2017ZZ02019);Key Clinical Specialty Projects in Shanghai No(shslczdzk05705)
地中海贫血和血友病是由基因异常引发的常见的遗传性血液病,难以根治且可遗传给下一代,造成严重的家庭和社会负担。基因治疗的出现为遗传性疾病提供了新的治疗方案,但自1990年第1项基因治疗临床试验被批准以来,30年间基因治疗的发展并不乐观。随着基因编辑技术的发展,尤其具有编辑效率高、操作简单、成本低等优势的第三代基因编辑技术CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/ CRISPR-associated protein 9)的发展,基因编辑介导的基因治疗越来越受到关注,有望根治地中海贫血和血友病等遗传性血液病。本文综述了近6年(2014~2020年)基于CRISPR/Cas9技术的β-地中海贫血和血友病基因治疗基础研究进展,总结了基于CRISPR/Cas9技术的基因治疗临床试验概况,并对CRISPR/Cas9技术用于基因治疗存在的问题和可能的解决方案进行探讨,以期为基于CRISPR/Cas9技术的遗传性血液病基因治疗相关研究提供参考。
关键词： CRISPR/Cas9; 基因治疗; 遗传性血液病; 临床试验
鲍莉雯, 周一叶, 曾凡一 . 基于CRISPR/Cas9技术的β-地中海贫血和血友病基因治疗研究进展[J]. 遗传, 2020 , 42(10) : 949 -964 . DOI: 10.16288/j.yczz.20-110
Thalassemia and hemophilia are common inherited blood disorders caused by genetic abnormalities. These diseases are difficult to cure and can be inherited to the next generation, causing severe family and social burden. The emergence of gene therapy provides a new treatment for genetic diseases. However, since its first clinical trial in 1990, the development of gene therapy has not been as optimistic in the past three decades as one could hope. The development of gene-editing technology, particularly the third generation gene-editing technology CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9), has given hope in such therapeutic approach for having advantages in high editing efficiency, simple operation, and low cost. Gene editing-mediated gene therapy has thus received increasing attention from the biomedical community. It has shown promises for the treatment of inherited blood disorders, such as thalassemia and hemophilia. This paper reviews the fundamental research progress of gene therapy for β-thalassemia and hemophilia based on CRISPR/Cas9 technology in the past six years. It also summarizes the CRISPR/Cas9-based clinical trials of gene therapy. The problems and possible solutions to this technology for gene therapy are also discussed, thereby providing a reference for the research on gene therapy of inherited blood disorders based on CRISPR/Cas9 technology.
Key words： CRISPR/Cas9; gene therapy; inherited blood disorders; clinical trials
| [1] | Taher AT, Weatherall DJ, Cappellini MD . Thalassaemia. Lancet, 2018,391(10116):155-167. |
| [2] | Farashi S, Harteveld CL . Molecular basis of α-thalassemia. Blood Cells Mol Dis, 2018,70:43-53. |
| [3] | Zeng YT, Huang SZ . Disorders of haemoglobin in China. J Med Genet, 1987,24(10):578-583. |
| [4] | Liu JW, Hong T, Qin X, Liang YM, Zhang P . Recent advance on genome editing for therapy of β-hemoglobinopathies. Hereditas(Beijing), 2018,40(2):95-103. |
| [4] | 刘佳伟, 洪涛, 秦鑫, 梁英民, 张萍 . β-血红蛋白病基因组编辑治疗的研究进展. 遗传, 2018,40(2):95-103. |
| [5] | Santagostino E, Fasulo MR . Hemophilia A and hemophilia B: different types of diseases? Semin Thromb Hemost, 2013,39(7):697-701. |
| [6] | Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF . T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science, 1995,270(5235):475-480. |
| [7] | Niu XR, Yin SM, Chen X, Shao TT, Li DL . Gene editing technology and its recent progress in disease therapy. Hereditas(Beijing), 2019,41(7):582-598. |
| [7] | 牛煦然, 尹树明, 陈曦, 邵婷婷, 李大力 . 基因编辑技术及其在疾病治疗中的研究进展. 遗传, 2019,41(7):582-598. |
| [8] | Nathwani AC, Davidoff AM, Tuddenham EGD . Advances in gene therapy for hemophilia. Hum Gene Ther, 2017,28(11):1004-1012. |
| [9] | Peyvandi F, Garagiola I . Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia. Haemophilia, 2019,25(5):738-746. |
| [10] | Zeng YT, Huang SZ, Ren ZR, Lu ZH, Zeng FY, Schechter AN, Rodgers GP . Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis. Br J Haematol, 1995,90(3):557-563. |
| [11] | Xie SY, Li W, Ren ZR, Huang SZ, Zeng FY, Zeng YT . Correction of β654-thalassaemia mice using direct intravenous injection of siRNA and antisense RNA vectors. Int J Hematol, 2011,93(3):301-310. |
| [12] | Xie SY, Ren ZR, Zhang JZ, Guo XB, Wang QX, Wang S, Lin D, Gong XL, Li W, Huang SZ, Zeng FY, Zeng YT . Restoration of the balanced alpha/beta-globin gene expression in beta654-thalassemia mice using combined RNAi and antisense RNA approach. Hum Mol Genet, 2007,16(21):2616-2625. |
| [13] | Davis R, Gurumurthy A, Hossain MA, Gunn EM, Bungert J . Engineering globin gene expression. Mol Ther Methods Clin Dev, 2018,12:102-110. |
| [14] | Elalfy MS, Adly AAM, Ismail EA, Elhenawy YI, Elghamry IR . Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. Eur J Haematol, 2013,91(6):522-533. |
| [15] | Xie F, Ye L, Chang JC, Beyer AI, Wang JM, Muench MO, Kan YW . Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res, 2014,24(9):1526-1533. |
| [16] | Ren YX, Xiao RD, Lou XM, Fang XD . Research advance and application in the gene therapy of gene editing technologies. Hereditas (Beijing), 2019,41(1):18-27. |
| [16] | 任云晓, 肖茹丹, 娄晓敏, 方向东 . 基因编辑技术及其在基因治疗中的应用. 遗传, 2019,41(1):18-27. |
| [17] | Garneau JE, Dupuis Mè, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath P, Magadán AH, Moineau S . The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature, 2010,468(7320):67-71. |
| [18] | Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao YJ, Pirzada ZA, Eckert MR, Vogel J, Charpentier E . CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature, 2011,471(7340):602-607. |
| [19] | Jinek M, Chylinski K, Fonfara I, Haue M, Doudna JA, Charpentier E . A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012,337(6096):816-821. |
| [20] | Mali P, Yang LH, Esvelt KM, Aach J, Guell M , DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science, 2013,339(6121):823-826. |
| [21] | Zhang JH, Adikaram P, Pandey M, Genis A, Simonds WF . Optimization of genome editing through CRISPR-Cas9 engineering. Bioengineered, 2016,7(3):166-174. |
| [22] | Chang HHY, Pannunzio NR, Adachi N, Lieber MR . Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol, 2017,18(8):495-506. |
| [23] | Li GL, Zhong CL, Mo JX, Quan R, Wu ZF, Li ZC, Yang HQ, Zhang XW . Advances in site-specific integration of transgene in animal genome. Hereditas (Beijing), 2017,39(2):98-109. |
| [23] | 李国玲, 钟翠丽, 莫健新, 全绒, 吴珍芳, 李紫聪, 杨化强, 张献伟 . 动物基因组定点整合转基因技术研究进展. 遗传, 2017,39(2):98-109. |
| [24] | Zong Y, Gao CX . Progress on base editing systems. Hereditas (Beijing), 2019,41(9):777-800. |
| [24] | 宗媛, 高彩霞 . 碱基编辑系统研究进展. 遗传, 2019,41(9):777-800. |
| [25] | Liang PP, Sun HW, Sun Y, Zhang XY, Xie XW, Zhang JR, Zhang Z, Chen YX, Ding CH, Xiong YY, Ma WB, Liu D, Huang JJ, Zhou SY . Effective gene editing by high-fidelity base editor 2 in mouse zygotes. Protein Cell, 2017,8(8):601-611. |
| [26] | Kim K, Ryu SM, Kim ST, Baek G, Kim D, Lim K, Chung E, Kim S, Kim JS . Highly efficient RNA-guided base editing in mouse embryos. Nat Biotechnol, 2017,35(5):435-437. |
| [27] | Lai KT, Huang GF, Su L, He YY . The prevalence of thalassemia in mainland China: evidence from epidemiological surveys. Sci Rep, 2017,7(1):920. |
| [28] | Niu XH, He WY, Song B, Ou ZH, Fan D, Chen YC, Fan Y, Sun XF . Combining single strand oligodeoxynucleotides and CRISPR/Cas9 to correct gene mutations in β-thalassemia-induced pluripotent stem cells. J Biol Chem, 2016,291(32):16576-16585. |
| [29] | Song B, Fan Y, He WY, Zhu DT, Niu XH, Wang D, Ou ZH, Luo M, Sun XF . Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system. Stem Cells Dev, 2015,24(9):1053-1065. |
| [30] | Liu YL, Yang Y, Kang XJ, Lin B, Yu Q, Song B, Gao G, Chen YY, Sun XF, Li XP, Bu L, Fan Y . One-step biallelic and scarless correction of a β-thalassemia mutation in patient-specific iPSCs without drug selection. Mol Ther Nucleic Acids, 2017,6:57-67. |
| [31] | Park SH, Lee CM, Dever DP, Davis TH, Camarena J, Srifa W, Zhang YK, Paikari A, Chang AK, Porteus MH, Sheehan VA, Bao G . Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. Nucleic Acids Res, 2019,47(15):7955-7972. |
| [32] | Wattanapanitch M, Damkham N, Potirat P, Trakarnsanga K, Janan M, U-pratya Y, Kheolamai P, Klincumhom N, Issaragrisil S,. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system. Stem Cell Res Ther, 2018,9(1):46. |
| [33] | Antony JS, Latifi N, Haque AKMA, Lamsfus-Calle A, Daniel-Moreno A, Graeter S, Baskaran P, Weinmann P, Mezger M, Handgretinger R, Kormann MSD . Gene correction of HBB mutations in CD34 + hematopoietic stem cells using Cas9 mRNA and ssODN donors . Mol Cell Pediatr, 2018,5(1):9. |
| [34] | Fang YD, Cheng Y, Lu D, Gong XL, Yang GH, Gong ZJ, Zhu YW, Sang X, Fan SY, Zhang JZ, Zeng FY . Treatment of β 654 -thalassaemia by TALENs in a mouse model . Cell Prolif, 2018,51(6):e12491. |
| [35] | Xu SQ, Luk K, Yao QM, Shen AH, Zeng J, Wu YX, Luo HY, Brendel C, Pinello L, Chui DHK, Wolfe SA, Bauer DE . Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia. Blood, 2019,133(21):2255-2262. |
| [36] | Park CY, Kim DH, Son JS, Sung JJ, Lee J, Bae S, Kim JH, Kim DW, Kim JS . Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell, 2015,17(2):213-220. |
| [37] | Peng Z, Zhou WC, Fu WQ, Du RQ, Jin L, Zhang F . Correlation between frequency of non-allelic homologous recombination and homology properties: evidence from homology-mediated CNV mutations in the human genome. Hum Mol Genet, 2015,24(5):1225-1233. |
| [38] | Sasaki M, Lange J, Keeney S . Genome destabilization by homologous recombination in the germ line. Nat Rev Mol Cell Biol, 2010,11(3):182-195. |
| [39] | Park CY, Kim J, Kweon J, Son JS, Lee JS, Yoo JE, Cho SR, Kim JH, Kim JS, Kim DW . Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. Proc Natl Acad Sci USA, 2014,111(25):9253-9258. |
| [40] | George CM, Alani E . Multiple cellular mechanisms prevent chromosomal rearrangements involving repetitive DNA. Crit Rev Biochem Mol Biol, 2012,47(3):297-313. |
| [41] | Zeng J, Wu YX, Ren CY, Bonanno J, Shen AH, Shea D, Gehrke JM, Clement K, Luk K, Yao QM, Kim R, Wolfe SA, Manis JP, Pinello L, Joung JK, Bauer DE . Therapeutic base editing of human hematopoietic stem cells. Nat Med, 2020,26(4):535-541. |
| [42] | Zhou CY, Sun YD, Yan R, Liu YJ, Zuo EW, Gu C, Han LX, Wei Y, Hu XD, Zeng R, Li YX, Zhou HB, Guo F, Yang H . Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis. Nature, 2019,571(7764):275-278. |
| [43] | Thein SL . Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells Mol Dis, 2018,70:54-65. |
| [44] | Mettananda S, Fisher CA, Hay D, Badat M, Quek L, Clark K, Hublitz P, Downes D, Kerry J, Gosden M, Telenius J, Sloane-Stanley JA, Faustino P, Coelho A, Doondeea J, Usukhbayar B, Sopp P, Sharpe JA, Hughes JR, Vyas P, Gibbons RJ, Higgs DR . Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia. Nat Commun, 2017,8(1):424. |
| [45] | Wu YX, Zeng J, Roscoe BP, Liu PP, Yao QM, Lazzarotto CR, Clement K, Cole MA, Luk K, Baricordi C, Shen AH, Ren CY, Esrick EB, Manis JP, Dorfman DM, Williams DA, Biffi A, Brugnara C, Biasco L, Brendel C, Pinello L, Tsai SQ, Wolfe SA, Bauer DE . Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med, 2019,25(5):776-783. |
| [46] | Martyn GE, Wienert B, Yang L, Shah M, Norton LJ, Burdach J, Kurita R, Nakamura Y, Pearson RCM, Funnell APW, Quinlan KGR, Crossley M . Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. Nat Genet, 2018,50(4):498-503. |
| [47] | Martyn GE, Wienert B, Kurita R, Nakamura Y, Quinlan KGR, Crossley M . A natural regulatory mutation in the proximal promoter elevates fetal globin expression by creating a de novo GATA1 site. Blood, 2019,133(8):852-856. |
| [48] | Antoniani C, Meneghini V, Lattanzi A, Felix T, Romano O, Magrin E, Weber L, Pavani G, Hoss SE, Kurita R, Nakamura Y, Cradick TJ, Lundberg AS, Porteus M, Amendola M, Nemer WE, Cavazzana M, Mavilio F, Miccio A . Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus. Blood, 2018,131(17):1960-1973. |
| [49] | Canver MC, Smith EC, Sher F, Pinello L, Sanjana NE, Shalem O, Chen DD, Schupp PG, Vinjamur DS, Garcia SP, Luc S, Kurita R, Nakamura Y, Fujiwara Y, Maeda T, Yuan GC, Zhang F, Orkin SH, Bauer DE . BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature, 2015,527(7577):192-197. |
| [50] | Liu PT, Keller JR, Ortiz M, Tessarollo L, Rachel RA, Nakamura T, Jenkins NA, Copeland NG . Bcl11a is essential for normal lymphoid development. Nat Immunol, 2003,4(6):525-532. |
| [51] | Li J, Lai YR, Shi LL . BCL11A down-regulation induces γ-globin in human β-thalassemia major erythroid cells. Hemoglobin, 2018,42(4):225-230. |
| [52] | Wang LR, Li LX, Ma YL, Hu HD, Li Q, Yang Y, Liu WB, Yin SM, Li W, Fu B, Kurita R, Nakamura Y, Liu M, Lai YR, Li DL . Reactivation of γ-globin expression through Cas9 or base editor to treat β-hemoglobinopathies. Cell Res, 2020,30(3):276-278. |
| [53] | Grevet JD, Lan XJ, Hamagami N, Edwards CR, Sankaranarayanan L, Ji XJ, Bhardwaj SK, Face CJ, Posocco DF, Abdulmalik O, Keller CA, Giardine B, Sidoli S, Garcia BA, Chou ST, Liebhaber SA, Hardison RC, Shi JW, Blobel GA . Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells. Science, 2018,361(6399):285-290. |
| [54] | Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, Magrin E, Schiller GJ, Payen E, Semeraro M, Moshous D, Lefrere F, Puy H, Bourget P, Magnani A, Caccavelli L, Diana JS, Suarez F, Monpoux F, Brousse V, Poirot C, Brouzes C, Meritet JF, Pondarré C, Beuzard Y, Chrétien S, Lefebvre T, Teachey DT, Anurathapan U, Ho PJ, von Kalle C, Kletzel M, Vichinsky E, Soni S, Veres G, Negre O, Ross RW, Davidson D, Petrusich A, Sandler L, Asmal M, Hermine O, Montalembert MD, Hacein-Bey-Abina S, Blanche S, Leboulch P, Cavazzana M,. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med, 2018,378(16):1479-1493. |
| [55] | Chen YH, Keiser MS, Davidson BL . Viral vectors for gene transfer. Curr Protoc Mouse Biol, 2018,8(4):e58. |
| [56] | Cunningham SC, Dane AP, Spinoulas A, Alexander IE . Gene delivery to the juvenile mouse liver using AAV2/8 vectors. Mol Ther, 2008,16(6):1081-1088. |
| [57] | George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen YF, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA,. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med, 2017,377(23):2215-2227. |
| [58] | Wang LL, Yang Y, Breton CA, White J, Zhang J, Che Y, Saveliev A, McMenamin D, He ZN, Latshaw C, Li MY, Wilson JM, . CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice. Blood, 2019,133(26):2745-2752. |
| [59] | Baliou S, Adamaki M, Kyriakopoulos AM, Spandidos DA, Panayiotidis M, Christodoulou I, Zoumpourlis V . CRISPR therapeutic tools for complex genetic disorders and cancer (Review). Int J Oncol, 2018,53(2):443-468. |
| [60] | Cyranoski D . CRISPR gene-editing tested in a person for the first time. Nature, 2016,539(7630):479. |
| [61] | Lu Y, Xue JX, Deng T, Zhou XJ, Yu K, Deng L, Huang MJ, Yi X, Liang MZ, Wang Y, Shen HG, Tong RZ, Wang WB, Li L, Song J, Li J, Su XX, Ding ZY, Gong YL, Zhu J, Wang YS, Zou BW, Zhang Y, Li YY, Zhou L, Liu YM, Yu M, Wang YQ, Zhang XW, Yin LM, Xia XF, Zeng Y, Zhou Q, Ying BW, Chen C, Wei YQ, Li WM, Mok T . Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med, 2020,26(5):732-740. |
| [62] | Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian LF, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi YY, Satpathy AT, Chang HY, Zhao YB, Lacey SF, June CH. CRISPR-engineered T cells in patients with refractory cancer. Science, 2020, 367(6481): eaba7365. |
| [63] | Xu L, Wang J, Liu YL, Xie LF, Su B, Mou DL, Wang LT, Liu TT, Wang XB, Zhang B, Zhao L, Hu LD, Ning HM, Zhang YF, Deng K, Liu LF, Lu XF, Zhang T, Xu J, Li C, Wu H, Deng HK, Chen H . CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med, 2019,381(13):1240-1247. |
| [64] | Wang DW, Wang K, Cai YJ . An overview of development in gene therapeutics in China. Gene Ther, 2020,27(7-8):338-348. |
| [65] | Park JH, Geyer MB, Brentjens RJ . CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood, 2016,127(26):3312-3320. |
| [66] | Fu YF, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD . High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol, 2013,31(9):822-826. |
| [67] | Cullot G, Boutin J, Toutain J, Prat F, Pennamen P, Rooryck C, Teichmann M, Rousseau E, Lamrissi-Garcia I, Guyonnet-Duperat V, Bibeyran A, Lalanne M, Prouzet- Mauléon V, Turcq B, Ged C, Blouin JM, Richard E, Dabernat S, Moreau-Gaudry F, Bedel A . CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations. Nat Commun, 2019,10(1):1136. |
| [68] | Lattanzi A, Meneghini V, Pavani G, Amor F, Ramadier S, Felix T, Antoniani C, Masson C, Alibeu O, Lee C, Porteus MH, Bao G, Amendola M, Mavilio F, Miccio A . Optimization of CRISPR/Cas9 delivery to human hematopoietic stem and progenitor cells for therapeutic genomic rearrangements. Mol Ther, 2019,27(1):137-150. |
| [69] | Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, Uchida N, Hendel A, Narla A, Majeti R, Weinberg KI, Porteus MH . CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature, 2016,539(7629):384-389. |
| [70] | Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE . Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol, 2016,34(2):184-191. |
| [71] | Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, Bacchetta R, Tsalenko A, Dellinger D, Bruhn L, Porteus MH . Chemically modified guide RNAs enhance CRISPR- Cas genome editing in human primary cells. Nat Biotechnol, 2015,33(9):985-989. |
| [72] | Vakulskas CA, Dever DP, Rettig GR, Turk R, Jacobi AM, Collingwood MA, Bode NM, McNeill MS, Yan SQ, Camarena J, Lee CM, Park SH, Wiebking V, Bak RO, Gomez-Ospina N, Pavel-Dinu M, Sun WC, Bao G, Porteus MH, Behlke MA,. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med, 2018,24(8):1216-1224. |
| [73] | Shen MW, Arbab M, Hsu JY, Worstell D, Culbertson SJ, Krabbe O, Cassa CA, Liu DR, Gifford DK, Sherwood RI . Predictable and precise template-free CRISPR editing of pathogenic variants. Nature, 2018,563(7733):646-651. |
| [74] | Yang YY, Zhang XB, Yi L, Hou ZZ, Chen JY, Kou XC, Zhao YH, Wang H, Sun XF, Jiang CZ, Wang YX, Gao SR . Na?ve induced pluripotent stem cells generated from β-thalassemia fibroblasts allow efficient gene correction with CRISPR/Cas9. Stem Cells Transl Med, 2016,5(2):267. |
| [75] | Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako M, Stojkovic M . Ethical and safety issues of stem cell-based therapy. Int J Med Sci, 2018,15(1):36-45. |
| [76] | Paes BCMF, Mo?o PD, Pereira CG, Porto GS, de Sousa Russo EM, Reis LCJ, Covas DT, Pican?o-Castro V,. Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation. Cell Biol Toxicol, 2017,33(3):233-250. |
| [77] | Tan YT, Ye L, Xie F, Beyer AI, Muench MO, Wang JM, Chen Z, Liu H, Chen SJ, Kan YW . Respecifying human iPSC-derived blood cells into highly engraftable hematopoietic stem and progenitor cells with a single factor. Proc Natl Acad Sci USA, 2018,115(9):2180-2185. |
| [78] | Uchida N, Haro-Mora JJ, Fujita A, Lee DY, Winkler T, Hsieh MM, Tisdale JF . Efficient generation of β-globin- expressing erythroid cells using stromal cell-derived induced pluripotent stem cells from patients with sickle cell disease. Stem Cells, 2017,35(3):586-596. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:
